March 18th, 2025
ALZpath Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025
CARLSBAD, California, March 18, 2025 — ALZpath, Inc.,a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced that it has been named to Fast Company‘s prestigious list of the World’s Most Innovative Companies of 2025.
Alzheimer’s disease and related dementias are expected to impact nearly 153 million people globally by 2050. ALZpath’s proprietary pTau217 antibody enables highly sensitive and accurate blood-based detection of phosphorylated tau at position 217 (pTau217), a key Alzheimer’s disease biomarker, supporting early-stage diagnosis well before symptoms appear.
“It is an honor to be named one of Fast Company’s World’s Most Innovative Companies,” said Mike Banville, CEO & President of ALZpath. “Many patients with Alzheimer’s today don’t have a clear diagnosis, in part because the most reliable current diagnostic methods are costly, invasive, and can only be administered at specialized facilities. Without a diagnosis, patients can’t get access to the latest treatments and clinical trials. In partnership with leading diagnostic companies, ALZpath is making our best-in-class antibody for detecting Alzheimer’s disease widely available in easy to administer, affordable blood tests, which we believe will vastly improve care and outcomes for millions of families facing Alzheimer’s disease.”
ALZpath’s pTau217 antibody is already integral to the most advanced blood tests in the world, including assays being developed for clinical use by Roche, Beckman Coulter, as well as other leading tests used in research from Bio-Techne, Alamar Biosciences, and Quanterix. Notably, Roche and Beckman Coulter’s pTau217 assays have received breakthrough device designation by the FDA, enabling accelerated review and the potential for widespread access in a variety of clinical settings in the U.S. and around the globe. Additionally, ALZpath partners with world-class laboratories, such as Neurocode, to further expand its reach and impact.
“Through our licensing agreements we are empowering researchers, clinicians, and industry partners to accelerate the discovery of new treatments,” said Jacob Hunter, Chief Business Officer of ALZpath. “Critically, this increased access supports the growing urgency to expand blood-based testing in research and clinical settings—enabling early identification of patients for novel treatments that have recently entered the clinical sphere, monitoring treatment response, and building robust evidence for the efficacy of novel therapies. Additionally, these efforts advance our understanding of Alzheimer’s disease and validate new targeted approaches to treat and potentially prevent the disease.”
This year’s list shines a spotlight on businesses that are shaping industry and culture through their innovations to set new standards and achieve remarkable milestones in all sectors of the economy.
“Our list of the Most Innovative Companies offers both a comprehensive look at innovation today and a playbook for the future,” said Fast Company editor-in-chief Brendan Vaughan. “This year, we recognize companies that are harnessing AI in deep and meaningful ways, brands that are turning customers into superfans by overdelivering for them, and challengers that are introducing bold ideas and vital competition to their industries. At a time when the world is rapidly shifting, these companies are charting the way forward.”
The full list of Fast Company’s Most Innovative Companies honorees can be found at fastcompany.com. It will also be available on newsstands beginning March 25.
About ALZpath
ALZpath is a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias. The novel ALZpath pTau217 antibody, integral to the most advanced, widely available blood-based tests to detect Alzheimer’s disease, is transforming its diagnosis and treatment monitoring, providing accurate and accessible tools for researchers and healthcare professionals worldwide. To help millions of patients in need, ALZpath democratizes access to its proprietary robust antibody, which is used by researchers, clinicians, and industry partners around the world to accelerate the discovery of new treatments and improve patient care.
To learn more about the company, please visit https://alzpath.bio/ and follow us on LinkedIn.
ALZpath Media Contact
Nechama Rosengarten
Nechama.Rosengarten@finnpartners.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on ALZpath’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause ALZpath’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in ALZpath’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, ALZpath assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
